Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Golden Cariboo (CSE:GCC) (OTC:GCCFF) Unlocks Cariboo Gold Potential (click to learn more) An Emerging Name in Cannabis: HERB (click to learn more) AI-Driven Wellness Play on the CSE (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News IN8bio Inc INAB

Healthcare Biotechnology
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:INAB)

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

GlobeNewswire 3 days ago

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

GlobeNewswire 9 days ago

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

GlobeNewswire January 12, 2026

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

GlobeNewswire December 19, 2025

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire November 6, 2025

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

GlobeNewswire October 29, 2025

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

GlobeNewswire October 27, 2025

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire August 7, 2025

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

GlobeNewswire June 9, 2025
View More News ››

Opinion & Analysis (NDAQ:INAB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:INAB)

Buy buddy buy because it's taking off this morning.

Otherwise FOMO
coolfooldumbguy - December 19, 2025

Using technical analysis for this one.

This stock is for swing trading purposes only because it is a big gamble for me anyway,so good luck to all of you guys out there,who are...
coolfooldumbguy - February 11, 2025

INAB ....Early a.m runner on NR....in PB mode

Below last opening support....might be done for the day ;
Iseneschal - April 24, 2023
View more Bullboard ››

Playboy Inc.

Playboy Inc.

Playboy, Inc. operates as a pleasure and leisure company in the United States, Australia, China, the United Kingdom, and ...
View More »

Podcasts